Management Team

Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board of Directors of Aurinia.

From March 2018 to April 2019, Peter served as the CEO of Cerecor Pharmaceuticals, Inc. (now Avalo Therapeutics, Inc.). From March 2014 to February 2018, Peter served as CEO and Chairman of Sucampo Pharmaceuticals, Inc. Sucampo was focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide and was sold in February 2018 to UK pharmaceutical company, Mallinckrodt PLC. From June 2013 to March 2014, Peter served as CEO and a member of the Board of Directors of Histogenics Corporation, a regenerative medicine company. From 2006 to 2013, he was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. From January 2010 to June 2013, Peter also served as President of MedImmune Ventures, a wholly-owned venture capital fund within the AstraZeneca Group.

Prior to serving as President of MedImmune, Peter was Senior Vice President, Commercial Operations of the company, responsible for its commercial, corporate development, and strategy functions. He has also held senior commercial roles at Centocor, Inc. (now Jansen Biotechnology, Johnson & Johnson) from 1998 to 2006 and at Boehringer Mannheim (now Roche Holdings) from 1996 to 1998.

Peter previously partnered with Governor Martin O’Malley to chair the Maryland Venture Fund Authority, whose vision was to oversee the implementation of Invest Maryland, a public-private partnership to spur venture capital investment in the state. In addition, he has extensive public and private board experience and has served in leadership roles on both BIO and PhRMA throughout the years. Peter earned an MBA from St. Joseph’s University and a B.S. from Western Connecticut State University.

Peter’s significant executive management, leadership, corporate development, and commercial operations experience in the biopharmaceutical industry enables him to provide valuable insight to our Board of Directors.

Max Donley joined Aurinia in 2019 and serves as the Executive Vice President, Operations and Strategy, leading the Quality, Manufacturing, Supply Chain, CMC, Facilities, HR, and IT organizations.

Max most recently led Human Resources, Information Technology and Facilities at Senseonics. Prior to that, Max was Executive Vice President of Global Human Resources, Information Technology, and Corporate Strategy at Sucampo Pharmaceuticals until its acquisition in February 2018. Max also served as Executive Vice President, Human Resources and Corporate Affairs at MedImmune, where he provided business-integrated leadership and delivered professional tools, programs and services to optimize MedImmune’s human capital investments worldwide.

Max received his B.A. from the University of Michigan and his MBA from George Mason University.

Greg Keenan, MD, joined Aurinia in 2023 as Chief Medical Officer. Dr. Keenan is an experienced physician who has played key roles in Phase 1 through Phase 4 clinical development of over 19 products, including small and large molecules as well as gene therapies across numerous therapeutic areas as well as numerous orphan and rare diseases. 

Most recently, he was the Chief Medical Officer at ValenzaBio, an early-stage biotech company developing biologic treatments for a variety of autoimmune and inflammatory diseases.  Prior to that he was Senior Vice President, Global Head of Medical and Drug Safety at Avrobio, a gene therapy company. Previously he served as Vice President, U.S., Medical Affairs and Head Medical Officer at AstraZeneca, which he joined following the company’s acquisition of Medimmune.  Earlier, he held roles of increasing responsibility at Human Genome Sciences Inc., and at Johnson and Johnson’s Centocor subsidiary.

Dr. Keenan began his career as a rheumatologist in academia, holding appointments at The Hospital of the University of Pennsylvania and the Children’s Hospital of Pennsylvania. He completed fellowships in pediatric and adult rheumatology at the University of Pennsylvania after having completed his residency in medicine/pediatrics at the LA County/University of Southern California Medical Center. Dr. Keenan holds an M.D. from Albany Medical College and a B.A. from Colby College.

Joe Miller joined Aurinia in April 2020 and currently serves as Chief Financial Officer. Joe has over two decades of experience in both public and private biotech and commercial-stage companies across the health sciences, biotech, and pharmaceutical sectors.

Most recently, Joe served as CFO, Principal Executive Officer, and Corporate Secretary at Avalo Therapeutics, (formerly Cerecor, Inc.), a publicly traded biotech company. Before Cerecor, Joe was the Vice President of Finance at Sucampo Pharmaceuticals Inc., where he was responsible for building out the finance organization to effectively support the company’s rapid growth. Before Sucampo, he served in various progressive finance and management roles at QIAGEN and Eppendorf. Joe began his career in the audit practice of KPMG LLP.

Joe earned his B.S. in accounting from Villanova University and is a Certified Public Accountant.

Joining Aurinia in 2020 (after having served as Aurinia’s Corporate Secretary since 2014), Stephen Robertson brings more than a decade of corporate and securities law experience across a number of industries, including life sciences. Prior to Aurinia, he served as Partner with the law firm Borden Ladner Gervais LLP.

Stephen is experienced in securities and corporate and commercial legal matters and has extensive experience with mergers and acquisitions, commercial agreements, and corporate governance matters.

Stephen has been recognized with several awards and honors, including being part of the 2020 edition of the Best Lawyers in Canada for Securities Law. He was previously an Adjunct Professor at the Allard School of Law of the University of British Columbia. He received his Bachelor of Laws degree from the University of Manitoba.

Dr. Prem Ramiya joined Aurinia in 2022 as Senior Vice President of Manufacturing and Supply Chain. Dr. Ramiya has over 25 years of experience in all phases of drug development, commercial supplies, technical transfers, working with global suppliers, and drug labelling, packaging, and distribution.

Prior to joining Aurinia, Dr. Ramiya was Vice President of CMC and Bio Analytical Operations at Cerus Corporation, a device and technology company focused on blood supply products. He has also held senior roles at Carbylan Therapeutics, Geron Corporation, and deCODE Genetics, as well as working at smaller biotech companies and for a contract manufacturer supplying active pharmaceutical ingredients to other biotech and pharmaceutical companies. Dr. Ramiya began his career at Abbott Labs.

Dr. Ramiya received his B.S. and M.S. in chemistry from Madurai Kamaraj University in India and his Ph.D. in organic chemistry from the Indian Institute of Science in Bangalore, India.

Andrea Christopher joined Aurinia in 2023 and oversees corporate communications and investor relations. She is responsible for developing corporate communications strategies that support company reputation and brand growth, strategic investor communications, and employee communications.

Mrs. Christopher has over 20 years of healthcare and pharmaceutical communications experience, with expertise in healthcare and scientific communications, public relations and marketing, employee engagement, and crisis and issues management.

From 2007 to 2023, Mrs. Christopher held successive communications roles at UCB, including a global role leading strategic external and internal communications for UCB’s 800-person immunology business unit. In her time at UCB, Mrs. Christopher worked across neurology and immunology teams, leading product launch communications campaigns, disease awareness initiatives, early and late-stage scientific communications, media relations efforts, executive visibility and thought leadership initiatives, and launched Advantage Hers, UCB’s first celebrity campaign for women of childbearing age living with chronic autoimmune diseases.

Prior to joining UCB, Mrs. Christopher was an Account Supervisor in the healthcare practice at Ogilvy Public Relations Worldwide. Mrs. Christopher began her career in the healthcare practice at Porter Novelli, a global public relations agency. 

Mrs. Christopher earned her B.A. from Syracuse University, where she majored in Public Affairs in Syracuse’s Maxwell School of Citizenship & Public Affairs.